[EN] COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS<br/>[FR] AGENTS PHARMACEUTIQUES EN COMBINAISON EN TANT QU'INHIBITEURS DE RSV
申请人:ENANTA PHARM INC
公开号:WO2019067864A1
公开(公告)日:2019-04-04
The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.
[EN] PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS<br/>[FR] LACTAMES SUBSTITUÉS PAR LE PIPÉRIDINYLE COMME MODULATEURS DE GPR119
申请人:ARRAY BIOPHARMA INC
公开号:WO2013066869A1
公开(公告)日:2013-05-10
Compounds of Formula (I) and pharmaceutically acceptable salts thereof in which X1, X2, X3, L, R3, R4, R5, R7 and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
申请人:Rodgers D. James
公开号:US20070135461A1
公开(公告)日:2007-06-14
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
The present invention provides a novel compound having an antiviral action, in particular, an HIV replication inhibiting action, as well as a pharmaceutical composition, in particular, an anti-HIV agent.
wherein, a broken line means the presence or absence of a bond; R
1
is substituted or unsubstituted alkyl etc., R
2
is substituted or unsubstituted alkyloxy etc.; n is 1 or 2; R
3
is a substituted or unsubstituted aromatic carbocyclic group; R
4
is a hydrogen atom etc.; R
5
is a substituted or unsubstituted aromatic carbocyclic group etc.; Y is a single bond etc.; R
6
is substituted or unsubstituted alkyl; R
7
is —Z—R
71
etc.; Z is —NR
72
—CO— etc.; R
71
is substituted or unsubstituted alkyl etc.; R
72
is a hydrogen atom etc.
Ligand-Free Palladium(II)-Catalyzed <i>ortho</i>
-C-H Chalcogenations of <i>N</i>
-Arylsulfonamide via Weak Coordination
作者:Linghui Gu、Xinyue Fang、Zhengyun Weng、Yupin Song、Wenbo Ma
DOI:10.1002/ejoc.201900050
日期:2019.2.28
The first palladium(II)‐catalyzed direct ortho‐C(sp2)–H chalcogenations of N‐arylsulfonamide via weak coordination have been achieved. This strategy features ligand/additive‐free conditions, broad substrate scope with excellent functional group tolerance and a high position selectivity.